Expanded Access Use of 131I-Omburtamab Intraventricular Radioimmunotherapy for Central Nervous System/Leptomeningeal Neoplasms
Latest Information Update: 17 Feb 2023
At a glance
- Drugs Omburtamab-I-131 (Primary)
- Indications CNS cancer; Ewing's sarcoma; Hepatoblastoma; Medulloblastoma; Meningeal carcinomatosis; Neuroblastoma; Retinoblastoma; Rhabdoid tumour; Rhabdomyosarcoma; Wilms' tumour
- Focus Expanded access; Therapeutic Use
- 11 Oct 2021 New trial record